NovaBridge Appoints Emmett Cunningham as Vice Chairman
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 19 2026
0mins
Should l Buy NBP?
NovaBridge Biosciences named Emmett Cunningham, Jr, MD, PhD, MPH, Co-Founder and Executive Chairman of Visara, as Vice Chairman of the NovaBridge Board of Directors. Dr. Cunningham will also join the Research and Development Committee of the Board.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy NBP?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on NBP
Wall Street analysts forecast NBP stock price to rise
2 Analyst Rating
2 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.450
Low
7.00
Averages
8.00
High
9.00
Current: 3.450
Low
7.00
Averages
8.00
High
9.00
About NBP
Novabridge Biosciences is a global biotechnology platform company. The Company combines deep business development expertise with agile translational clinical development to identify, accelerate, and advance breakthrough assets. Its differentiated pipeline includes givastomig, a bispecific antibody (Claudin 18.2 x 4-1BB), and VIS-101, a bifunctional biologic, targeting VEGF-A and ANG2. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed to treat Claudin 18.2-positive gastric cancer and other gastrointestinal malignancies. VIS-101 targets VEGF-A and ANG-2 to provide more potent and durable treatment benefits for patients with wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). VIS-101 is completing a large, randomized, dose-ranging Phase 2 study for wet AMD.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NovaBridge Announces VIS-101 Clinical Data Update
- Clinical Trial Progress: NovaBridge is conducting a randomized dose-ranging Phase 2a study for VIS-101, aimed at providing more effective treatment for patients with wet age-related macular degeneration (AMD), which is expected to significantly enhance patient quality of life.
- Global Rights Control: Visara, as a majority-owned subsidiary of NovaBridge, holds global development and commercialization rights to VIS-101 outside Greater China and certain Asian territories, which will strongly support the company's expansion in international markets.
- Virtual Update Meeting: NovaBridge plans to host a virtual business update call on March 9, 2026, to review clinical data for VIS-101, aiming to bolster investor confidence in the company's R&D progress.
- Innovative Drug Development: VIS-101, as a dual VEGF-A/ANG-2 inhibitor, has the potential to become the best-in-class treatment for wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO), potentially transforming the current standard of care.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their future performance, which could influence investor decisions and market sentiment.
- AMZN Stock Outlook: Analysts' opinions on Amazon (AMZN) stock indicate mixed views on its future growth potential, prompting investors to pay close attention to the latest ratings and recommendations when considering purchases.
- Impact of Rating Changes: Upgrades and downgrades from analysts can lead to stock price volatility, necessitating that investors closely monitor these changes to timely adjust their investment strategies and optimize their portfolios.
- Market Sentiment Reflection: Changes in analyst ratings not only affect individual stock performance but can also impact overall market sentiment, urging investors to consider these factors comprehensively for informed investment decisions.
See More
NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs
- Chairman's Purchase Plan: Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million in the company's ADSs through his controlled entity in open market transactions, reflecting confidence in the company's future growth.
- Positive Clinical Data: The recent positive dose expansion data for givastomig from the Phase 1b study reinforces NovaBridge's clinical development capabilities and market potential in treating gastric cancer.
- Global Platform Development: NovaBridge is committed to accelerating access to innovative medicines by combining deep business development expertise with agile clinical development, showcasing the strategic value of its global biotechnology platform.
- Diverse Pipeline: The company's pipeline includes potential best-in-class therapies like givastomig and VIS-101, targeting gastric cancer and other malignancies, demonstrating its diversity and innovation in the biopharmaceutical sector.
See More
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
- Market Transformation: The precision medicine sector is projected to grow from $138 billion in 2026 to over $537 billion by 2035, marking a shift towards modular biologics that creates substantial market opportunities for companies like GT Biopharma.
- New Drug Application: GT Biopharma submitted an IND for GTB-5550 to the FDA in December 2025, targeting the B7-H3 protein to treat various solid tumors, which is expected to significantly enhance the company's competitiveness in cancer treatment.
- Clinical Trial Progress: The planned Phase 1 trial for GTB-5550 will evaluate its efficacy across seven distinct metastatic disease cohorts, potentially providing critical clinical data to further advance the company's product pipeline.
- Dual Program Advancement: GT Biopharma is concurrently advancing its Phase 1 trial of GTB-3650, having successfully treated multiple patients with a favorable safety profile, which is expected to significantly expand its addressable patient population.
See More
NovaBridge Reports Positive Phase 1b Results for Givastomig in Gastric Cancer with 77% Response Rate
- Clinical Trial Progress: NovaBridge's Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 shows an overall response rate of 77% for the 8 mg/kg cohort and 73% for the 12 mg/kg cohort, indicating significant potential for this therapy in treating HER2-negative metastatic gastric cancer.
- Survival Data: The median progression-free survival (PFS) reached 16.9 months in the 8 mg/kg group, while PFS data for the 12 mg/kg group remains immature, highlighting the promising outlook of this treatment in extending patient survival.
- Safety Analysis: The combination therapy was generally well tolerated, with a safety profile comparable to standard care, and immune-related gastritis was observed to correlate with improved clinical outcomes, suggesting both safety and efficacy warrant attention.
- Future Research Plans: NovaBridge plans to initiate a global randomized Phase 2 study in Q1 2026 to evaluate both doses against standard care, with detailed Phase 1b dose expansion data expected to be presented at a medical conference later in 2026, further advancing the clinical development pipeline.
See More
NovaBridge Biosciences Reports 77% Response Rate in HER2-Negative Gastric Cancer Study
- Significant Efficacy: NovaBridge's Phase 1b combination study of givastomig with nivolumab and chemotherapy in HER2-negative metastatic gastric cancer demonstrated an overall response rate of 77% at 8 mg/kg, indicating the potential to transform first-line treatment options.
- Extended Survival: The median progression-free survival reached 16.9 months at the 8 mg/kg dose, with a six-month landmark progression-free survival rate of 73%, providing patients with a longer survival period and enhancing the clinical value of the therapy.
- Good Safety Profile: The combination therapy exhibited a safety profile comparable to current standard-of-care treatments, demonstrating good tolerability, which may position it as a viable option for future therapies and improve patient treatment experiences.
- Stock Price Surge: NovaBridge's shares rose over 11% in pre-market trading after closing at $4.37, up 2.34%, reflecting the market's positive reaction to the study results and potentially attracting more investor interest in its future developments.
See More
NovaBridge Announces VIS-101 Clinical Data Update
- Clinical Trial Progress: NovaBridge is conducting a randomized dose-ranging Phase 2a study for VIS-101, aimed at providing more effective treatment for patients with wet age-related macular degeneration (AMD), which is expected to significantly enhance patient quality of life.
- Global Rights Control: Visara, as a majority-owned subsidiary of NovaBridge, holds global development and commercialization rights to VIS-101 outside Greater China and certain Asian territories, which will strongly support the company's expansion in international markets.
- Virtual Update Meeting: NovaBridge plans to host a virtual business update call on March 9, 2026, to review clinical data for VIS-101, aiming to bolster investor confidence in the company's R&D progress.
- Innovative Drug Development: VIS-101, as a dual VEGF-A/ANG-2 inhibitor, has the potential to become the best-in-class treatment for wet AMD, diabetic macular edema (DME), and retinal vein occlusion (RVO), potentially transforming the current standard of care.
See More
Wall Street Analysts Adjust Ratings
- Analyst Rating Changes: Top Wall Street analysts have adjusted their ratings on several companies, reflecting varying market perspectives on their future performance, which could influence investor decisions and market sentiment.
- AMZN Stock Outlook: Analysts' opinions on Amazon (AMZN) stock indicate mixed views on its future growth potential, prompting investors to pay close attention to the latest ratings and recommendations when considering purchases.
- Impact of Rating Changes: Upgrades and downgrades from analysts can lead to stock price volatility, necessitating that investors closely monitor these changes to timely adjust their investment strategies and optimize their portfolios.
- Market Sentiment Reflection: Changes in analyst ratings not only affect individual stock performance but can also impact overall market sentiment, urging investors to consider these factors comprehensively for informed investment decisions.
See More
NovaBridge Biosciences' Chairman Plans to Buy $5 Million in ADSs
- Chairman's Purchase Plan: Fu Wei, Executive Chairman of NovaBridge Biosciences, intends to purchase up to $5 million in the company's ADSs through his controlled entity in open market transactions, reflecting confidence in the company's future growth.
- Positive Clinical Data: The recent positive dose expansion data for givastomig from the Phase 1b study reinforces NovaBridge's clinical development capabilities and market potential in treating gastric cancer.
- Global Platform Development: NovaBridge is committed to accelerating access to innovative medicines by combining deep business development expertise with agile clinical development, showcasing the strategic value of its global biotechnology platform.
- Diverse Pipeline: The company's pipeline includes potential best-in-class therapies like givastomig and VIS-101, targeting gastric cancer and other malignancies, demonstrating its diversity and innovation in the biopharmaceutical sector.
See More
GT Biopharma Submits IND for GTB-5550 Targeting $362 Billion Solid Tumor Market
- Market Transformation: The precision medicine sector is projected to grow from $138 billion in 2026 to over $537 billion by 2035, marking a shift towards modular biologics that creates substantial market opportunities for companies like GT Biopharma.
- New Drug Application: GT Biopharma submitted an IND for GTB-5550 to the FDA in December 2025, targeting the B7-H3 protein to treat various solid tumors, which is expected to significantly enhance the company's competitiveness in cancer treatment.
- Clinical Trial Progress: The planned Phase 1 trial for GTB-5550 will evaluate its efficacy across seven distinct metastatic disease cohorts, potentially providing critical clinical data to further advance the company's product pipeline.
- Dual Program Advancement: GT Biopharma is concurrently advancing its Phase 1 trial of GTB-3650, having successfully treated multiple patients with a favorable safety profile, which is expected to significantly expand its addressable patient population.
See More
NovaBridge Reports Positive Phase 1b Results for Givastomig in Gastric Cancer with 77% Response Rate
- Clinical Trial Progress: NovaBridge's Phase 1b study evaluating givastomig in combination with nivolumab and mFOLFOX6 shows an overall response rate of 77% for the 8 mg/kg cohort and 73% for the 12 mg/kg cohort, indicating significant potential for this therapy in treating HER2-negative metastatic gastric cancer.
- Survival Data: The median progression-free survival (PFS) reached 16.9 months in the 8 mg/kg group, while PFS data for the 12 mg/kg group remains immature, highlighting the promising outlook of this treatment in extending patient survival.
- Safety Analysis: The combination therapy was generally well tolerated, with a safety profile comparable to standard care, and immune-related gastritis was observed to correlate with improved clinical outcomes, suggesting both safety and efficacy warrant attention.
- Future Research Plans: NovaBridge plans to initiate a global randomized Phase 2 study in Q1 2026 to evaluate both doses against standard care, with detailed Phase 1b dose expansion data expected to be presented at a medical conference later in 2026, further advancing the clinical development pipeline.
See More
NovaBridge Biosciences Reports 77% Response Rate in HER2-Negative Gastric Cancer Study
- Significant Efficacy: NovaBridge's Phase 1b combination study of givastomig with nivolumab and chemotherapy in HER2-negative metastatic gastric cancer demonstrated an overall response rate of 77% at 8 mg/kg, indicating the potential to transform first-line treatment options.
- Extended Survival: The median progression-free survival reached 16.9 months at the 8 mg/kg dose, with a six-month landmark progression-free survival rate of 73%, providing patients with a longer survival period and enhancing the clinical value of the therapy.
- Good Safety Profile: The combination therapy exhibited a safety profile comparable to current standard-of-care treatments, demonstrating good tolerability, which may position it as a viable option for future therapies and improve patient treatment experiences.
- Stock Price Surge: NovaBridge's shares rose over 11% in pre-market trading after closing at $4.37, up 2.34%, reflecting the market's positive reaction to the study results and potentially attracting more investor interest in its future developments.
See More
